



Published on NAVADHI Market Research (<https://www.navadhi.com>)

[Home](#) > Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis

Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis



Publication ID:

NAV0319010

Publication Date:

March 03, 2019

Pages:

30

Countries:

[Global](#) [1]

Publication License Type *

Single User License (PDF), \$350.00

Enterprise License (PDF), \$500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Add to wish list



As per NAVADHI Market Research, the [global pharmaceutical industry](#) [2] will be worth **USD 1.57 trillion** by 2023.

Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases.


Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.

GILEAD SCIENCES 2018 PERFORMANCE AT A GLANCE

COMPANY SALES, EBITDA & EPS



TOP SELLING GEOGRAPHY



R&D HIGHLIGHTS



TOP SELLING DRUG



SALES BY BUSINESS UNIT



* Full Year 2018 Non-GAAP Diluted EPS



Graphics are solely for presentation purpose only, for more detail please refer to actual market research report

Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.

For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead’s business following the acquisition of Kite.

Spanning over 30 pages and 18 exhibits, “Gilead Sciences, Inc. - Company Snapshot & SWOT

Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report

- This report provides detailed information about Gilead Sciences, Inc. including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.

1. Executive Summary

Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report
Research Methodology

2. Growth Drivers and Inhibitors for Global Pharmaceuticals Market

3. Company Profile

3.1 Gilead Sciences Inc.

3.1.1. Company Profile

3.1.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain

3.1.3 Gilead Sciences, Inc.: Financial Performance

3.1.4 Gilead Sciences, Inc.: Geography wise Performance

3.1.5 Gilead Sciences, Inc.: Business Strategy

3.1.5.1 Gilead Sciences, Inc. Revenue by Business Segment

3.1.6 SWOT Analysis of Gilead Sciences, Inc.

Strengths

Weaknesses

Opportunities

Threats

4. Current and Future Trends in Pharmaceutical Market

List of Exhibits

Notes

Company Information

List of Exhibits

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market

Exhibit 3.1 Key Information of Gilead Sciences, Inc.

Exhibit 3.2 Contact Information of Gilead Sciences, Inc.

Exhibit 3.3 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain

Exhibit 3.4 Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)

Exhibit 3.5 Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)

Exhibit 3.6 Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018

Exhibit 3.7 Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)

Exhibit 3.8 Gilead Sciences, Inc. Business Segment Revenue Share 2018

Exhibit 3.9 Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)

Exhibit 3.10 Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)

Exhibit 3.11 Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
Exhibit 3.12 Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
Exhibit 3.13 Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
Exhibit 3.14 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
Exhibit 3.15 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
Exhibit 3.16 Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
Exhibit 3.17 SWOT Analysis of Gilead Sciences, Inc.

Gilead Sciences, Inc.

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

About Us



Intelligence Rediscovered

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Information

- [About Us](#)
- [Publications](#)
- [FAQs](#)
- [Privacy Policy](#)
- [Terms & Conditions](#)
- [Careers](#)
- [Press Releases](#)
- [Contact](#)

Source URL: <https://www.navadhi.com/publications/gilead-sciences-inc-company-snapshot-swot-analysis>

Links

[1] <https://www.navadhi.com/countries/global>

[2] <https://www.navadhi.com/publications/global-pharmaceuticals-industry-analysis-and-trends-2023>